1) Review the chemistry and mechanism of action of Ra-223. 2) Understand the approved indication for Ra-223. 3) Illustrate the techniques and procedures for radium administration using a case-based approach.
Radium-223 is an alpha-emitting radiopharmaceutical approved for use in men with castration-resistant prostate carcinoma. THe use of radium in a clinical setting will be discussed, including the rationale, patient eligibility, administration, and follow-up, as well as radiation safety precautions and handling. Illustrative cases will be presented.
Rohren, E,
Ra-223 Therapy for Bone Metastases. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL.
http://archive.rsna.org/2014/14001408.html
